Crispr Therapeutics AG  

(Public, NASDAQ:CRSP)   Watch this stock  
Find more results for CRSP
-0.35 (-1.16%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 28.81 - 30.96
52 week 11.63 - 30.96
Open 30.12
Vol / Avg. 386,254.00/689,898.00
Mkt cap 1.36B
P/E     -
Div/yield     -
EPS -0.32
Shares 41.02M
Beta     -
Inst. own 43%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1035.07% -449.30%
Operating margin -987.43% -1096.98%
EBITD margin - -1299.96%
Return on average assets -33.75% -9.20%
Return on average equity -52.61% -22.75%
Employees 93 -
CDP Score - -


Aeschenvorstadt 36
BASEL, 4051

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Officers and directors

Rodger Novak M.D. Chairman of the Board of Directors, President, Founder
Age: 49
Bio & Compensation  - Reuters
Samarth Kulkarni Ph.D. Chief Executive Officer
Age: 38
Bio & Compensation  - Reuters
Kala Subramanian Ph.D. Senior Vice President - Strategic Development and Operations
Age: 49
Bio & Compensation  - Reuters
Megan Wherry Menner Senior Vice President of Human Resources
Bio & Compensation  - Reuters
Sven Ante Lundberg M.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Tony Ho Head of Research and Development
Bio & Compensation  - Reuters
Jim Kasinger General Counsel, Secretary to the Board of Directors
Bio & Compensation  - Reuters
Tyler M. Dylan-Hyde J.D., Ph.D. Chief Legal Officer
Age: 55
Bio & Compensation  - Reuters
Jon Terrett Ph.D. Head of Immuno-Oncology Research and Translation
Bio & Compensation  - Reuters
Ali Behbahani M.D. Independent Director
Age: 40
Bio & Compensation  - Reuters